Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.29 - aureolysin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abscess
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Anaphylaxis
Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides.
Anemia, Dyserythropoietic, Congenital
Aberrant regulation of complement by the erythrocytes of hereditary erythroblastic multinuclearity with a positive acidified serum lysis test (HEMPAS).
Anti-Glomerular Basement Membrane Disease
Autoimmune kidney diseases.
Arthritis, Experimental
Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y.
Arthritis, Infectious
Impact of staphylococcal protease expression on the outcome of infectious arthritis.
Atypical Hemolytic Uremic Syndrome
A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.
aureolysin deficiency
A haplotype in CFH family genes confers high risk of rare glomerular nephropathies.
Autoimmune Diseases
Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.
Bacterial Infections
Staphylococcus aureus: Staphylokinase.
Brain Injuries
Deficiency of complement receptors CR2/CR1 in Cr2?/? mice reduces the extent of secondary brain damage after closed head injury.
Brain Injuries, Traumatic
Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury.
Brain Ischemia
Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Carcinoma, Hepatocellular
Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.
Cardiovascular Diseases
Purification and in vivo stability and half-life of recombinant lipid modified staphylokinase.
[Staphylokinase--a specific plasminogen activator]
Chagas Disease
Microparticles and infectious diseases.
[Total hemolytic complement, C3 and C3 convertase levels in cardiac and indeterminate forms of Chagas' disease]
Coronary Thrombosis
Conjugation with Eight-Arm PEG Markedly Improves the In Vitro Activity and Prolongs the Blood Circulation of Staphylokinase.
Effects of recombinant staphylokinase on coronary thrombosis in Chinese experimental miniature swine.
[Thrombolytic effects of recombinant staphylokinase on coronary thrombosis in miniature pigs].
Craniocerebral Trauma
Deficiency of complement receptors CR2/CR1 in Cr2?/? mice reduces the extent of secondary brain damage after closed head injury.
Cystic Fibrosis
Staphylokinase production by clinical Staphylococcus aureus strains.
Dermatitis, Atopic
[A study of the single nucleotide polymorphism fragments of the AUR gene metalloprotease strains of Staphylococcus aureus isolated from the skin of patients with atopic dermatitis].
Dermatitis, Contact
Combination treatment with lipoteichoic acids isolated from Lactobacillus plantarum and Staphylococcus aureus alleviates atopic dermatitis via upregulation of CD55 and CD59.
Embolic Stroke
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model.
Embolism
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
[Thrombolysis by staphylokinase in rabbits with experimental pulmonary embolus]
Encephalomyelitis
Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.
Encephalomyelitis, Autoimmune, Experimental
Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.
Treatment of an encephalitogenic peptide from guinea pig myelin basic protein with alpha-protease and thermolysin. Isolation of fragments and determination of cleavage sites.
Glomerulonephritis
An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis.
C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway.
Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis.
The significance of in vitro activation of guinea pig complement in glomeruli of human renal biopsy materials from varied subtypes of glomerulonephritis.
Glomerulonephritis, Membranoproliferative
A Humanized Antibody That Regulates the Alternative Pathway Convertase: Potential for Therapy of Renal Disease Associated with Nephritic Factors.
Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis.
Autoimmune kidney diseases.
C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Management of membranoproliferative glomerulonephritis type II with plasmapheresis.
Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Recurrent disseminated gonococcal infection in a patient with hypocomplementemia and membranoproliferative glomerulonephritis.
Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).
Glomerulonephritis, Membranous
Autoimmune kidney diseases.
Hemoglobinuria
Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.
Hemoglobinuria, Paroxysmal
Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.
Hepatitis C
Inhibition of c3 convertase activity by hepatitis C virus as an additional lesion in the regulation of complement components.
Hypersensitivity
On the immunogenicity of recombinant staphylokinase in patients and in animal models.
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.
Infections
Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection.
Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.
Limitations of Staphylokinase as a Marker for Staplylococcus aureus Invasive Infections in Humans.
Plasminogen activation by staphylokinase enhances local spreading of S. aureus in skin infections.
Protease-Mediated Growth of Staphylococcus aureus on Host Proteins Is opp3 Dependent.
SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation.
Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis.
Staphylococcus aureus Fatty Acid Kinase FakA Modulates Pathogenesis during Skin Infection via Proteases.
Staphylococcus aureus osteomyelitis: bad to the bone.
Staphylokinase and ABO group phenotype: new players in Staphylococcus aureus implant-associated infections development.
Staphylokinase production by clinical Staphylococcus aureus strains.
Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity.
Influenza in Birds
Modification of the hemagglutinin cleavage site allows indirect activation of avian influenza virus H9N2 by bacterial staphylokinase.
Ischemic Stroke
Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
Kidney Failure, Chronic
Long-term successful liver-kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency.
Lipodystrophy
C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Lupus Erythematosus, Systemic
A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway.
Mastitis
Staphylococcus aureus stimulates urokinase-type plasminogen activator expression by bovine mammary cells.
Myocardial Infarction
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
An enzyme-linked immunosorbent assay for host cell protein contaminants in recombinant PEGylated staphylokinase mutant SY161.
Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction.
Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II).
Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS).
Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model.
Conjugation with Eight-Arm PEG Markedly Improves the In Vitro Activity and Prolongs the Blood Circulation of Staphylokinase.
Construction and characterization of a novel staphylokinase variant with thrombin-inhibitory activity.
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.
Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase.
Effects of recombinant staphylokinase on coronary thrombosis in Chinese experimental miniature swine.
High-level secretory production of intact, biologically active staphylokinase from Bacillus subtilis.
Human alpha -defensins neutralize fibrinolytic activity exerted by staphylokinase.
Interactions of staphylokinase with human platelets.
Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase.
Mechanism of action and thrombolytic potential of staphylokinase.
Newer thrombolytic drugs for acute myocardial infarction.
Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase.
On the immunogenicity of recombinant staphylokinase in patients and in animal models.
Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally monoPEGylated staphylokinase.
Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction.
Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization.
Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase.
Third-generation thrombolytic drugs.
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase.
Toxicology studies with recombinant staphylokinase and with SY 161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant.
[A randomized multicenter trial comparing recombinant staphylokinase with recombinant tissue-type plasminogen activator in patients with acute myocardial infarction]
[Staphylokinase for a better thrombolytic treatment of heart and platelet diseases]
[Staphylokinase--a specific plasminogen activator]
[Thrombolytic effects of recombinant staphylokinase on coronary thrombosis in miniature pigs].
Neoplasms
Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate.
Nephritis
Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
Autoimmune kidney diseases.
Neuroinflammatory Diseases
Deficiency of complement receptors CR2/CR1 in Cr2?/? mice reduces the extent of secondary brain damage after closed head injury.
Osteomyelitis
Staphylococcus aureus osteomyelitis: bad to the bone.
Pancreatitis
Synergetic effect of yihuo qingyi decoction (see text) and recombinant staphylokinase in treatment of severe acute pancreatitis of rats.
[Effect of the recombinant staphylokinase on pancreatic ischemia in severe acute pancreatitis of rats]
Paracoccidioidomycosis
Activation of human complement system Paracoccidioides brasiliensis and its deposition on the yeast form cell surface.
Pregnancy Complications
The role of complement in the antiphospholipid syndrome.
Pulmonary Embolism
A contemporary approach to thrombolytic therapy for pulmonary embolism.
Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Human alpha -defensins neutralize fibrinolytic activity exerted by staphylokinase.
Thrombolysis in pulmonary embolism: a debatable indication.
Renal Insufficiency
Distinct roles for C3a and C5a in complement-induced tubulointerstitial injury.
Rheumatic Diseases
C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Rhinitis
[Effectiveness and tolerance of the C3 convertase inhibitor, N-acetyl-aspartyl-magnesium glutamate in perennial rhinitis. Results of a double-blind, placebo-controlled study]
Sepsis
Staphylococcus aureus: Staphylokinase.
Shock, Septic
Association Between the Methicillin Resistance of Staphylococcus aureus Isolated from Slaughter Poultry, Their Toxin Gene Profiles and Prophage Patterns.
Detection and molecular characterisation of methicillin-resistant Staphylococcus aureus isolated from raw meat in the retail market.
Direct, Specific and Rapid Detection of Staphylococcal Proteins and Exotoxins Using a Multiplex Antibody Microarray.
Enterotoxin production by Staphylococcus aureus isolates from cases of septicaemia and from healthy carriers.
Microarray based study on virulence-associated genes and resistance determinants of Staphylococcus aureus isolates from cattle.
Regulation of exoprotein gene expression in Staphylococcus aureus by agar.
Soft Tissue Infections
Staphylokinase production by clinical Staphylococcus aureus strains.
Stroke
Thrombolytic therapy in acute ischemic stroke - basic concepts.
Thrombocytopenia
Crosstalk between the coagulation and complement systems in sepsis.
Thrombosis
A fusion protein with improved thrombolytic effect and low bleeding risk.
A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model.
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.
Current Clinical Experience with Staphylokinase in Arterial Thrombosis.
Design, production, and characterization of an engineered biotin ligase (BirA) and its application for affinity purification of staphylokinase produced from Bacillus subtilis via secretion.
Enhancement of secretion and extracellular stability of staphylokinase in Bacillus subtilis by wprA gene disruption.
Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis.
Fibrin-specific fibrinolysis induced by recombinant staphylokinase.
High-level expression of a biologically active staphylokinase in Pichia pastoris.
New derivative of staphylokinase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats.
New thrombolytic strategies.
Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase.
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits.
Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.
[Staphylokinase--a specific plasminogen activator]
[Thrombolytic effects of recombinant staphylokinase on coronary thrombosis in miniature pigs].
Uterine Cervical Neoplasms
Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.
Vascular System Injuries
Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
Fusion proteins with anticoagulant and fibrinolytic properties: functional studies and structural considerations.
Venous Thrombosis
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.
Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis.
Newer thrombolytic drugs for acute myocardial infarction.